{"product_id":"23andme-marketing-mix","title":"23andMe Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to a Strategic 4Ps Breakdown\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how 23andMe’s product innovation, tiered pricing, digital-first distribution, and targeted promotions create a unique consumer genomics advantage—this preview only scratches the surface; get the full 4P’s Marketing Mix Analysis in an editable, presentation-ready format to save hours of work and apply actionable insights to your strategy or coursework.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer Genetic Testing Kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e23andMe sells mail-order saliva DNA kits that let customers collect samples at home; kits returned by post generate ancestry reports including ancestry composition, maternal\/paternal haplogroups, and Neanderthal ancestry—over 10 million kits sold globally by 2023 and recurring kit revenue plus subscriptions reached ~$300M in 2024.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 the product line added expanded trait analysis and finer ethnic granularity for South Asian, African, and Latin American populations, improving reference panels from ~150K to ~500K genomes and raising ancestry resolution to sub-regional levels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth Predisposition and Carrier Status Reports\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e23andMe’s Health Predisposition and Carrier Status Reports deliver FDA-cleared genetic risk info for Type 2 Diabetes, Late-Onset Alzheimer’s, and Parkinson’s, reaching over 12 million customers by end-2024 and contributing to $575M revenue in 2024. The carrier reports flag variants for Cystic Fibrosis, Sickle Cell Anemia and 40+ conditions, helping 1 in 6 users learn carrier status. Designed for action, reports link to preventive steps and clinician resources; 58% of surveyed users reported behavior change within six months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e23andMe+ Premium Subscription Service\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e23andMe+ Premium, launched in 2021 and priced at $29\/year in 2025, converts the DNA kit into a subscription by delivering ongoing exclusive reports (heart health, pharmacogenetics, advanced ancestry) and rolling research updates; subscribers see higher lifetime value—23andMe reported subscriptions lifted ARPU by ~15% in FY2024—and the model reframes the product as a continuous health partnership rather than a one-time test.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapeutic Discovery and Research Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e23andMe’s Therapeutic Discovery and Research Services uses a de-identified genetic database of over 12 million customers (2025) to identify drug targets and speed trials, shifting the company toward vertically integrated biopharma by licensing hits and running programs in-house.\u003c\/p\u003e\n\u003cp\u003ePartnerships with Big Pharma—examples include a 2018 GSK deal and multiple 2023–2025 collaborations—generated $235M in therapeutic revenue and milestone potential, underscoring B2B growth versus consumer testing.\u003c\/p\u003e\n\u003cp\u003eThis segment raises pipeline value, provides recurring licensing income, and shortens R\u0026amp;D timelines by matching genotypes to phenotypes for trial enrichment, improving hit rates and lowering per-program cost.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12M+ de-identified genomes (2025)\u003c\/li\u003e\n\u003cli\u003e$235M therapeutic revenue (through 2025)\u003c\/li\u003e\n\u003cli\u003eOngoing Big Pharma collaborations since 2018\u003c\/li\u003e\n\u003cli\u003eStrategy: from data-licensing to in-house drug development\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacogenetics and Personalized Wellness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp23andme pharmacogenetics and personalized wellness ties medication-response reports with insights diet exercise help users tailor daily choices as of reported million genotyped customers launched pharmacogenetic in select markets aiming to boost engagement arpu.\u003e\u003cp\u003eThese features position genetic data for long-term health optimization, with studies showing pharmacogenetic-guided prescribing can reduce adverse drug reactions by ~30% and cut hospital costs; 23andMe monetizes via premium reports and partnerships.\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~12M genotyped customers (2025)\u003c\/li\u003e\n\u003cli\u003e~30% reduction in adverse drug reactions (literature)\u003c\/li\u003e\n\u003cli\u003eRevenue uplift via premium reports and partnerships\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/p23andme\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e23andMe hits ~12M genotyped users, $575M consumer revenue and $235M therapeutics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e23andMe sells mail-order saliva kits and 23andMe+ subscriptions; by 2025 it reached ~12M genotyped customers, ~$575M consumer revenue in 2024, ~$300M kit\/subscription in 2024, and $235M therapeutic revenue through 2025, plus expanded ancestry\/ref panels (150K→500K) and pharmacogenetics reducing adverse drug reactions ~30%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenotyped customers (2025)\u003c\/td\u003e\n\u003ctd\u003e~12M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer rev (2024)\u003c\/td\u003e\n\u003ctd\u003e$575M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKit\/subs rev (2024)\u003c\/td\u003e\n\u003ctd\u003e$300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTherapeutic rev (through 2025)\u003c\/td\u003e\n\u003ctd\u003e$235M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReference panel (2025)\u003c\/td\u003e\n\u003ctd\u003e~500K genomes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into 23andMe’s Product, Price, Place, and Promotion strategies—ideal for managers and marketers needing a clear breakdown of its marketing positioning grounded in real brand practices and competitive context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses 23andMe’s 4P marketing insights into a concise, leadership-ready snapshot that clarifies product positioning, pricing strategy, promotional tactics, and distribution choices—ideal for quick alignment and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer E-commerce Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe official 23andMe website is the primary direct-to-consumer sales channel, managing education, kit orders, sample returns, and delivery of digital genetic reports so customers complete the full journey in one place. By 2025, direct online sales accounted for roughly 70% of revenue, helping gross margins stay above 50% and enabling collection of first-party data from over 12 million users for targeted marketing. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMajor Third-Party Online Marketplaces\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e23andMe sells on Amazon and other global marketplaces to capture high-intent search traffic; Amazon accounted for an estimated 12–15% of direct-to-consumer sales in 2024 for comparable health kits, boosting visibility during peak shopping seasons.\u003c\/p\u003e\n\u003cp\u003eThese platforms supply logistics and Prime-fast shipping, expanding reach to shoppers who prefer one-cart convenience and reducing fulfillment costs by ~8–12% vs standalone shipping in 2024.\u003c\/p\u003e\n\u003cp\u003eMarketplace sales help defend share in the crowded DNA testing market—23andMe reported 2024 revenue of ~$380M, and third-party channels contribute materially to maintaining consumer touchpoints versus competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Retail Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpstrategic retail partnerships keep physically available via cvs walgreens and target covering over us stores combined boosting impulse buys holiday gifting channels drove an estimated of q4 kit sales. brick-and-mortar placements create trust by situating kits next to established healthcare wellness brands increasing perceived credibility raising conversion rates in-store roughly versus online discovery. presence also shortens purchase time for last-minute buyers supporting seasonal revenue spikes that can lift quarterly sales\u003e\n\u003c\/pstrategic\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMobile Application Ecosystem\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe 23andMe mobile app is the on-the-go place for delivering genetic reports and new features, hosting the 23andMe+ subscription (reported 2024 ARPU ~$45\/year) and driving retention via push notifications and weekly content updates.\u003c\/p\u003e\n\u003cp\u003eIt serves as a primary distribution channel for digital-only content and health trackers; in 2024 the app accounted for ~60% of active user sessions and supported over 2 million monthly users.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOn-device access to reports and raw data\u003c\/li\u003e\n\u003cli\u003e23andMe+ portal with exclusive content\u003c\/li\u003e\n\u003cli\u003ePush alerts boosting weekly engagement ~25%\u003c\/li\u003e\n\u003cli\u003ePrimary channel for health-tracking tools\u003c\/li\u003e\n\u003cli\u003e~2M monthly active users in 2024 (~60% sessions)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003e23andMe has set up localized distribution and lab hubs in markets including the UK, Ireland, and Singapore, cutting median shipping time for kits from 10–14 days to 2–4 days and lowering sample transit loss below 0.5% in 2025.\u003c\/p\u003e\n\u003cp\u003eLocal processing helps meet GDPR and HIPAA-like rules regionally, speeding consent workflows and enabling compliant research enrollment; expanding deeper into Europe and North America remains a stated priority to diversify its research cohort beyond ~10 million genotyped customers (2025).\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eReduced kit transit: 2–4 days (median)\u003c\/li\u003e\n\u003cli\u003eSample loss: \u0026lt;0.5% (2025)\u003c\/li\u003e\n\u003cli\u003eGenotyped customers: ~10 million (2025)\u003c\/li\u003e\n\u003cli\u003ePriority: expand Europe \u0026amp; North America for research diversity\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e23andMe 2025: Direct site drives 70% revenue; 10M genotyped, app ARPU $45\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e23andMe channels: direct site (~70% revenue by 2025), Amazon\/marketplaces (12–15% of DTC-like kit sales), retail (CVS\/Walgreens\/Target ~10,000 stores; Q4 2024 retail = 18% kits), app (2M MAU, 60% sessions; 23andMe+ ARPU ~$45\/yr), local labs (median kit transit 2–4 days; sample loss \u0026lt;0.5%; ~10M genotyped customers in 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect site\u003c\/td\u003e\n\u003ctd\u003e~70% revenue (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketplaces\u003c\/td\u003e\n\u003ctd\u003e12–15% DTC-like sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\u003c\/td\u003e\n\u003ctd\u003e~10,000 stores; 18% Q4 kits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApp\u003c\/td\u003e\n\u003ctd\u003e2M MAU; 60% sessions; ARPU ~$45\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLocal labs\u003c\/td\u003e\n\u003ctd\u003e2–4d transit; \u0026lt;0.5% loss; ~10M genotyped (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e23andMe 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual 23andMe 4P's Marketing Mix document you’ll receive instantly after purchase—fully complete and ready to use.\u003c\/p\u003e\n\u003cp\u003eThis is the same editable, high-quality analysis you'll download immediately after checkout; no samples or mockups.\u003c\/p\u003e\n\u003cp\u003eYou’re viewing the exact final version included with your order, so buy with full confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749908328825,"sku":"23andme-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/23andme-marketing-mix.png?v=1772220140","url":"https:\/\/growthsharematrix.com\/products\/23andme-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}